A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs TAK 935 (Primary)
  • Indications Dravet syndrome; Epilepsy; Lennox-Gastaut syndrome; Tuberous sclerosis
  • Focus Adverse reactions
  • Sponsors Takeda
  • Most Recent Events

    • 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society
    • 03 Dec 2017 According to an Ovid Theraprutics media release, data from this trial was presented at the American Epilepsy Society (AES) 71st Annual Meeting.
    • 21 Nov 2017 According to an Ovid Therapeutics media release, data from this trial will be presented at the American Epilepsy Society (AES) 71st Annual Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top